Tharimmune (THAR) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
31 Mar, 2026Executive summary
Completed first full year as a digital asset treasury company, focusing on Canton Coin (CC) and network participation.
Secured $545 million in private placement and $55 million in underwritten offering to fund digital asset strategy.
Appointed new leadership and board members with deep regulatory and trading expertise.
Approved as a Super Validator, supporting over 1 million daily transactions and $9 trillion in monthly volume.
Financial highlights
Held 3,339,569,946 CC valued at $501.8 million as of December 31, 2025.
Cash balance of $17 million at year-end 2025.
No revenue recognized in 2025 or 2024, reflecting early-stage digital asset focus.
Operating expenses rose to $20.1 million in 2025 from $12.4 million in 2024, driven by SG&A and $6 million in non-recurring compensation.
Recorded $22 million unrealized loss on digital assets in 2025.
Net loss of $35.9 million ($1.12 per diluted share) in 2025, up from $12.2 million ($9.41 per diluted share) in 2024.
Accumulated deficit reached $72.8 million by year-end 2025.
Outlook and guidance
Plans to expand ecosystem partnerships and invest in network builders.
Aims to mobilize CC holdings for yield and value accretion as new network features emerge.
Intends to streamline costs and focus on high-value initiatives, reducing expenses after Q1 2026.
Latest events from Tharimmune
- All proposals, including director elections and equity plan amendment, were approved.THAR
EGM 20262 Feb 2026 - Board nominees are confirmed as independent; voting process for the special meeting is unchanged.THAR
Proxy Filing27 Jan 2026 - Shareholders to vote on director elections, equity issuances, and plan amendments at virtual meeting.THAR
Proxy Filing16 Jan 2026 - $2B shelf registration supports blockchain and biotech growth, following a $545M PIPE raise.THAR
Registration Filing9 Jan 2026 - Shareholders to vote on board expansion, equity issuances, and a 7M-share plan increase.THAR
Proxy Filing6 Jan 2026 - Shareholders to vote on new directors, warrant issuances, and a 7M-share equity plan increase.THAR
Proxy Filing16 Dec 2025 - Raised $545M for a digital asset treasury strategy; offering is secondary, no new capital raised.THAR
Registration Filing16 Dec 2025 - Biotech registers 1.44M shares for resale from $2.02M private placement, funding R&D.THAR
Registration Filing16 Dec 2025 - Biotech registers 1M+ shares for resale after $2.08M private placement, funding R&D amid risks.THAR
Registration Filing16 Dec 2025